{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-25-000818","form_type":"8-K","ticker":"ZEOX","cik":"0001557376","company_name":"Zeo ScientifiX, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.984920+00:00","generated_at":"2026-05-27T00:01:12.857621+00:00","sec_items":["1.01","5.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Zeo ScientifiX enters joint development MOU with BioXtek, appoints Dr. Peter Everts as CSO","bullets":["Binding MOU with BioXtek for joint development, manufacturing, marketing, and funding arrangement.","ZEO to relocate to BioXtek's 11,000 sq ft Pompano Beach facility by May 31, 2025.","Parties to form 50/50 SPE to pursue FDA BLA approval for membrane products.","Dr. Peter Everts appointed CSO; salary $220K first year, option for 25,000 shares at $3.05.","Severance: 1/4 month salary per 3 months after 90-day initial period."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-25-000818","json":"https://secwatch.observer/filing/0001829126-25-000818.json","markdown":"https://secwatch.observer/filing/0001829126-25-000818.md","text":"https://secwatch.observer/filing/0001829126-25-000818.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625000818/0001829126-25-000818-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625000818/zeoscientifix_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:01:12.857621+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d2f9283aa8","claim":"Dr. Peter A. M. Everts was appointed as Chief Scientific and Technology Officer at Zeo ScientifiX, Inc..","evidence_excerpt":"Effective February 7, 2025, Dr. Peter A. M. Everts, Ph.D. (“ Dr. Everts” ) was appointed the Company’s Chief Scientific and Technology Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557376/000182912625000818/0001829126-25-000818-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Scientific and Technology Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}